Barclays raised the firm’s price target on Sangamo (SGMO) to $9 from $3 and keeps an Overweight rating on the shares post the Q3 report. Following the recent announcement of an accelerated approval pathway alignment with the FDA, the Q3 call focused on the Fabry program’s path forward, with partnership discussions in late stage, the analyst tells investors in a research note. The firm sees a high probability of positive data in Q3 of 2025 and FDA approval in 2026, and expects a deal announcement in the near term.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue